Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM310 in Chronic Rhinosinusitis With Nasal Polyps
CTR20221480Phase 3Completed
- Sponsor
- Keymed Biosciences
- Start
- Jun 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic rhinosinusitis with nasal polyps (CRSwNP) comparing CM310 with Placebo (2 arms). Primary endpoints: Change from baseline in nasal polyp score at week 24 and Change from baseline in nasal congestion score at week 24. Started Jun 2022; status: completed.
02
Drugs
stapokibart
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on CTR20221480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221480.